Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing BioCryst Pharmaceuticals’ filings can feel like decoding enzyme structures—the science is intricate and the stakes are high. Pipeline updates, royalty agreements, and FDA milestones are buried across hundreds of pages, while insider moves ahead of trial readouts appear with little notice. If finding those details in a 250-page 10-K keeps you up at night, you’re not alone.
Stock Titan solves this problem by pairing every BioCryst document with AI-powered summaries that translate biotech jargon into plain English. Need the BioCryst quarterly earnings report 10-Q filing in minutes? Our engine highlights HAE revenue trends and cash-burn metrics. Want real-time alerts on BioCryst insider trading Form 4 transactions? We surface who bought, who sold, and how it aligns with clinical catalysts—no EDGAR digging required.
Our coverage spans all form types: 10-K annual reports, 8-K material events explained, proxy statement executive compensation details, and BioCryst Form 4 insider transactions real-time. Each filing includes expert notes so you can quickly understand trial-phase risks, partnership economics, and upcoming regulatory hurdles. Practical use cases abound:
- Track executive stock transactions Form 4 before pivotal data releases
- Compare segment spending across R&D programs via annual report 10-K simplified
- Monitor 8-K disclosures on manufacturing or FDA feedback
With comprehensive, minute-by-minute updates and AI context, understanding BioCryst SEC documents with AI becomes straightforward—helping you make informed decisions faster.
BioCryst Pharmaceuticals (Nasdaq:BCRX) filed an 8-K announcing it has signed a definitive Stock Purchase Agreement dated June 27 2025 to sell 100% of the equity of BioCryst Ireland Ltd. and its subsidiaries to Neopharmed Gentili S.p.A.
No purchase price was disclosed, and closing is subject to customary regulatory approvals, financing by the buyer and other conditions. The company warns of possible business disruption, transaction costs and relationship changes during the interim period.
The press release is furnished as Exhibit 99.1; no pro-forma financials were included. Management makes forward-looking statements regarding timing, benefits and risks of the divestiture.
BioCryst Pharmaceuticals (NASDAQ:BCRX) announced that the FDA has extended the PDUFA goal date for their NDA regarding ORLADEYO oral granules for pediatric HAE patients aged 2-11 years. The 3-month extension moves the target action date to December 12, 2025. The extension was triggered by the company's submission of additional final reports and formulation data, which the FDA classified as a major amendment requiring full review.
The delay affects the potential expansion of ORLADEYO, currently approved for other age groups, into the pediatric hereditary angioedema market segment. The FDA requires additional time to review the supplementary data for safety and efficacy in young patients.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
What is the core business of BioCryst Pharmaceuticals Inc?
Which therapeutic areas does BioCryst primarily target?
How does BioCryst approach drug discovery and development?
What distinguishes BioCryst in the competitive biotechnology market?
Where are BioCryst’s research and operational centers located?
How does the company ensure regulatory compliance?
What role does innovation play in BioCryst’s strategy?
